Florfenicol, Terbinafine, Betamethasone Acetate

Verify with FDA CVM →

557 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
557
Total Reports
24
Deaths Reported
430.0%
Death Rate

Active Ingredients

Florfenicol, Terbinafine, Betamethasone Acetate

Administration Routes

Auricular (Otic)UnknownOphthalmicTopicalOralOther

Species Affected

Dog 419
Cat 112
Unknown 18
Human 8

Most Affected Breeds

Domestic Shorthair 75
Retriever - Labrador 45
Unknown 26
Shih Tzu 23
Chihuahua 21
Dog (unknown) 21
Maltese 20
Bulldog - French 18
Terrier - Yorkshire 17
Retriever - Golden 16

Most Reported Reactions

Deafness 79
Lack of efficacy - NOS 56
Vomiting 45
Head shake - ear disorder 43
Not eating 41
Lethargy (see also Central nervous system depression in 'Neurological') 40
Loss of hearing 38
Head tilt - ear disorder 37
Ataxia 37
Corneal ulcer 34
Horner's syndrome 31
Ear discharge 31

Outcome Breakdown

Outcome Unknown
299 (55.3%)
Recovered/Normal
136 (25.1%)
Ongoing
63 (11.6%)
Recovered with Sequela
19 (3.5%)
Euthanized
13 (2.4%)
Died
11 (2.0%)

Data Summary

Metric Value
Total adverse event reports 557
Reports involving death 24
Case-fatality rate (reported events) 430.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Florfenicol, Terbinafine, Betamethasone Acetate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 557 adverse event reports referencing Florfenicol, Terbinafine, Betamethasone Acetate, including 24 reports in which the animal died — a 430.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Florfenicol, Terbinafine, Betamethasone Acetate. Reported administration routes include Auricular (Otic), Unknown, Ophthalmic, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Florfenicol, Terbinafine, Betamethasone Acetate reports are Dog (419 reports), Cat (112 reports), Unknown (18 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (75), Retriever - Labrador (45), Unknown (26) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Florfenicol, Terbinafine, Betamethasone Acetate are Deafness (79), Lack of efficacy - NOS (56), Vomiting (45), Head shake - ear disorder (43). Of the 541 reports with a coded outcome, Outcome Unknown is the leading category at 55.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Florfenicol, Terbinafine, Betamethasone Acetate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial